ABVX (Abivax) Ending Cash Position: $551.93 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABVX Abivax SA ABVX
10 GF Score
Price $130.93
! 1 Warning Sign
View Full Analysis

What is Abivax Ending Cash Position?

Abivax ABVX +0.75% 10 Ending Cash Position is $551.93 Mil as of Mar. 2026. GuruFocus rates ABVX with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Abivax's Ending Cash Position for the quarter that ended in Mar. 2026 was $551.93 Mil.

Abivax's quarterly Ending Cash Position declined from Sep. 2025 ($692.14 Mil) to Dec. 2025 ($605.02 Mil) and declined from Dec. 2025 ($605.02 Mil) to Mar. 2026 ($551.93 Mil).

Abivax's annual Ending Cash Position declined from Dec. 2023 ($274.75 Mil) to Dec. 2024 ($151.02 Mil) but then increased from Dec. 2024 ($151.02 Mil) to Dec. 2025 ($605.02 Mil).

Abivax Ending Cash Position Related Terms

Abivax Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Abivax's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Ending Cash Position Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.59 28.55 274.75 151.02 605.02

Abivax Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.97 70.30 692.14 605.02 551.93
ABVX
10GF Score
Abivax SA ABVX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Abivax's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=174.417+430.601
=605.02

Abivax's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=597.324+-45.39
=551.93

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $551.93 Mil mean?
Abivax (ABVX) has a Ending Cash Position of $551.93 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abivax and its competitors.
Is Abivax's Ending Cash Position too high?
Abivax's current Ending Cash Position is $551.93 Mil. Overall, Abivax has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's Ending Cash Position compare to VRTX and REGN?
Abivax's Ending Cash Position of $551.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abivax and its competitors. Abivax's current Ending Cash Position is $551.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (ABVX) has a current Ending Cash Position of $551.93 Mil. The current Ending Cash Position is $551.93 Mil. Abivax's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Abivax (ABVX), the current Ending Cash Position is $551.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
10GF Score

Get the complete analysis for ABVX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$130.93
Price